1 Jun 2019
Clin Cancer Res: Surufatinib in advanced, well-differentiated neuroendocrine tumors
Upcoming Investor Events
Learn More
THE LANCET :
FRESCO-2, a global Phase III study of fruquintinib in refractory metastatic colorectal cancer
Learn More
THE LANCET HAEMATOLOGY:
Sovleplenib for primary immune thrombocytopenia patients in China
Learn More
European Lung Cancer Congress 2022
Final OS results and subgroup analysis of savolitinib Phase II study in METex14+ NSCLC
Learn More
Latest News
13 Jul 2021First Commercial Sale of ORPATHYS® in China Triggering a US$25 million Milestone Payment from AstraZenecaRead more 12 Jul 2021HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global OfferingRead more 6 Jul 2021HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL-295 in Patients with Advanced Solid Tumors in ChinaRead more
2 Jul 2021HUTCHMED to Announce 2021 Half-Year Financial ResultsRead more 1 Jul 2021U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine TumorsRead more 30 Jun 2021HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong KongRead more 23 Jun 2021HUTCHMED Announces Pricing of Global OfferingRead more See all
Scientific Publications
26 Jun 2018
JAMA: Fruquintinib vs Placebo in Previously Treated Metastatic Colorectal Cancer
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
LONDON AIM
13
HKEX
13
IN-HOUSE DISCOVERED
CLINICAL STAGE CANCER
DRUG CANDIDATES
CLINICAL STAGE CANCER
DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
PRODUCTS IN CHINA
1
APPROVED & MARKETED
PRODUCT IN THE U.S.
PRODUCT IN THE U.S.
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13 REGISTRATION STUDIES
INCLUDING 13 REGISTRATION STUDIES
5,000
PERSONNEL ACROSS
THE GROUP
THE GROUP
OUR SCIENCE
Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.
FOLLOW HUTCHMED ON SOCIAL MEDIA
